HOME >> BIOLOGY >> NEWS
Columbia team finds treatment that corrects cellular defect at the root of heart failure

NEW YORK - Researchers at Columbia University have shown for the first time that beta blockers - drugs used to treat cardiovascular disease - can correct a specific defect in failing hearts.

"Up until now we have been treating symptoms but not the cause of heart failure," says Dr. Andrew R. Marks, Clyde and Helen Wu Professor of Molecular Cardiology at Columbia University College of Physicians & Surgeons and principal investigator of the study. "Our research shows that we can treat the cause." Dr. Marks also serves as director of Columbia's Center for Molecular Cardiology and is professor of medicine and pharmacology. The findings will be published in the Dec. 4 issue of the journal Circulation.

Heart failure, the leading cause of death in the developed world, occurs when the heart is too weak to sustain proper circulation. Some patients in heart failure receive left-ventricular assist devices (LVADs), which are implanted in the chest to help pump the blood and give the patient's own heart a rest as he or she waits for a heart transplant. Patients in heart failure may also be given drugs to improve symptoms. But heart transplant is the only way to cure heart failure.

Dr. Marks' research demonstrates that defects in the calcium channel controlling heart muscle function occur in heart failure. The membrane surrounding a cell contains a small calcium channel stimulated by the electrical impulses driving heart rhythm. When stimulated, this calcium channel triggers another, larger calcium channel within the cell, called the ryanodine receptor, to release calcium ions. The rush of calcium ions then signals the heart muscle to contract powerfully. The ryanodine receptor sits at the surface of the sarcoplasmic reticulum, a sac containing calcium ions, and is the major gatekeeper for calcium ion release.

The more calcium released through the ryanodine receptor, the stronger the contraction of the heart. Dr. Marks and his colleagues have
'"/>

Contact: Annie Bayne
as862@columbia.edu
Columbia University Medical Center
11-Dec-2001


Page: 1 2 3

Related biology news :

1. Columbia research to examine gene influence on severity of peridontal disease, therapy response
2. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies
3. Worlds largest scientific society holds regional meeting in Columbia, Mo.
4. New Columbia Genomic Center of Excellence aims to speed genetic targeting of medicines
5. Columbia offers new ecology program in Dominican Republic
6. Columbia professor receives 2003 National Golden Apple for Teaching Excellence
7. Columbia investigators win 2003 Gairdner International Award for research
8. Gene newly identified by Columbia researchers may improve hair removal
9. Years of research, thought lead geologist to propose new supercontinent Columbia
10. ESA Corporate Award winner 2001: Weyerhaeuser Company Limited British Columbia Coastal Forest Project Team
11. Columbia receives NYSTAR grant - Brain imaging studies will accelerate medical science and create jobs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... , ... April 24, 2019 , ... ... announces today the award of U.S. patent 10,191,929, “Systems and Methods for SNP ... and more efficient to conduct a variety of advanced bioinformatic analyses, including SNP ...
(Date:4/18/2019)... and WALNUT CREEK, Calif. (PRWEB) , ... April ... ... management solution for the healthcare industry, today announced the launch of mSource® AI ... processing to extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased ...
(Date:4/16/2019)... ... April 16, 2019 , ... HealthLink International, experts ... its new medical device facility on Friday, April 12. Headquartered in the Netherlands, ... new facility includes 108,500 square feet and houses 32 employees enabling HealthLink to ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Agents for sales and service organizations, today announced global availability of Inference ... providers and enterprises of all sizes to harness the power of Google’s ...
(Date:4/15/2019)... ... April 15, 2019 , ... ... of a $2 million bench plant expansion to increase production of methylene malonate ... the design and construction of Sirrus’ full-scale production facility, which is scheduled to ...
(Date:4/9/2019)... , ... April 09, 2019 , ... ... focused on increasing the capacity of life sciences organizations to accelerate innovation and ... Assurance platform in the past 12 months. , USDM’s Cloud Assurance ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
Breaking Biology Technology:
Cached News: